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Nonsteroidal anti-inflammatory drugs (NSAIDs) can cause seri-
ous gastrointestinal (GI) injury including jejunal/ileal mucosal 
ulceration, bleeding, and even perforation in susceptible patients. 
The underlying mechanisms are largely unknown, but they are 
distinct from those related to gastric injury. Based on recent 
insights from experimental models, including genetics and phar-
macology in rodents typically exposed to diclofenac, indomethacin, 
or naproxen, we propose a multiple-hit pathogenesis of NSAID 
enteropathy. The multiple hits start with an initial pharmacoki-
netic determinant caused by vectorial hepatobiliary excretion 
and delivery of glucuronidated NSAID or oxidative metabolite 
conjugates to the distal small intestinal lumen, where bacterial 
β-glucuronidase produces critical aglycones. The released agly-
cones are then taken up by enterocytes and further metabolized 
by intestinal cytochrome P450s to potentially reactive interme-
diates. The “first hit” is caused by the NSAID and/or oxidative 
metabolites that induce severe endoplasmic reticulum stress or 
mitochondrial stress and lead to cell death. The “second hit” is 
created by the significant subsequent inflammatory response 
that would follow such a first-hit injury. Based on these putative 
mechanisms, strategies have been developed to protect the entero-
cytes from being exposed to the parent NSAID and/or oxidative 
metabolites. Among these, a novel strategy already demonstrated 
in a murine model is the selective disruption of bacteria-specific 
β-glucuronidases with a novel small molecule inhibitor that does 
not harm the bacteria and that alleviates NSAID-induced enter-
opathy. Such mechanism-based strategies require further investi-
gation but provide potential avenues for the alleviation of the GI 
toxicity caused by multiple NSAID hits.
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Small intestinal injury induced by nonsteroidal anti- 
inflammatory drugs (NSAIDs) has been increasingly recognized 
as a frequent and serious adverse drug reaction associated with the 
majority of the nonselective cyclooxygenase (COX)–1/2 inhibi-
tors. The underlying mechanisms are incompletely understood, 
and currently, there are no clinically approved effective therapies 
available. This review critically evaluates recent insights into the 
mechanisms and proposes novel strategies to alleviate NSAID 
enteropathy by mechanism-based therapeutic approaches.
CLINICAL SIGNIFICANCE OF NSAID ENTEROPATHY 
AND CURRENT EXPERIMENTAL MODELS
Clinical Significance
NSAID-associated enteropathy features high morbidity and 
mortality rates and is therefore a significant clinical challenge, 
causing a major burden on the health care system (Davies et al., 
2000; Scarpignato and Hunt, 2010). In the United States, the 
annual number of hospitalizations for serious NSAID-related 
gastrointestinal (GI) complications has been estimated to be 
greater than 100,000 patients and associated with approximately 
16,500 deaths (Wolfe et  al., 1999). This is understandable as 
NSAIDs are among the most widely consumed pharmaceuticals 
in the world (Scarpignato and Hunt, 2010). The most commonly 
appreciated GI complications are gastric injury, but the more distal 
parts of the GI tract are also frequently affected. For example, 
serious injury to the small intestine has been estimated to account 
for one third of all NSAID-associated complications (Scarpignato 
and Hunt, 2010). These can manifest as ulceration and bleeding of 
the mucosa, inflammation, and, in rare cases, perforation (Allison 
et al., 1992; Bjarnason et al., 1993; Wolfe et al., 1999). Typically, 
ulcers present as necrotic or apoptotic injury of enterocytes that 
may involve deeper layers of the mucosa, with loss of villi and an 
acute inflammatory cell infiltrate. These adverse drug reactions 
in the duodenum, jejunum, and ileum are collectively termed 
enteropathy. (NSAIDs can also cause colonopathy [Davies, 
1995], but this is beyond the scope of this review.) The increasing 
use of novel diagnostic tools including video capsule endoscopy 
has revealed that, unexpectedly, approximately two thirds of both 
long-term (> 3 months) and short-term (< 1 week) NSAID users 
exhibit mild or more severe forms of drug-induced lesions in the 
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small intestine (Björnsson et al., 2008; Fortun and Hawkey, 2007; 
Maiden, 2009). In addition, many GI lesions in apparent “control 
subjects” were found to be attributable to non-prescription use of 
NSAIDs (Sidhu et al., 2010). In spite of its high incidence, there 
are currently no approved effective therapies to prevent or treat 
NSAID enteropathy.
This lack of enteric-protective therapies is in part due to an 
incomplete understanding of the underlying mechanisms of 
NSAID-induced GI damage (Whittle, 2004). Importantly, the 
successfully used current therapies to treat gastric injury do not 
protect from small intestinal injury. For example, the widely used 
proton pump inhibitors (PPIs; e.g., omeprazole, lansoprazole) or 
histamine H2-receptor antagonists (e.g., cimetidine, famotidine) 
are not effective in protecting from intestinal injury in patients. In 
fact, in animal models and in patients, these therapies have been 
shown to aggravate the extent of enteropathy (Daniell, 2012; 
Satoh et al., 2012; Wallace, 2012).
Gastrointestinal injury is primarily associated with the tra-
ditional, nonselective COX-1/2 inhibitors, whereas the selec-
tive COX-2 inhibitors were initially thought to be GI-safe. 
However, a number of reports based on capsule endoscopy sug-
gest that the incidence of jejunal/ileal injury induced by chronic 
use of selective COX-2 inhibitors may be equally high as that 
caused by certain nonselective COX inhibitors (Maehata et al., 
2012; Maiden, 2009; Maiden et al., 2007). The reasons are not 
completely understood but could include a key role of COX-2 
in maintaining small bowel mucosal integrity.
Experimental Models
Although NSAIDs have been clinically used for decades and 
their potential to induce GI toxicity has long been recognized, the 
current understanding of the mechanisms responsible for these 
adverse drug effects is still incomplete. More recently, experi-
mental animal models have shed more light on the mechanistic 
pathways. Both rats and mice have been extensively used to emu-
late the human disease although rodents are clearly more sensitive 
than humans to NSAID-induced GI toxicity. The reasons under-
lying this high susceptibility are not entirely clear but may be due 
to the fact that in rodents, the hepatobiliary excretion of NSAID 
and metabolite conjugates and the extent of enterohepatic cycling 
are higher than in humans (Boelsterli and Ramirez-Alcantara, 
2011). Another reason is that rodents harbor more enteric bac-
teria than humans (DeSesso and Jacobson, 2001), which could 
play a role in bacteria-catalyzed hydrolysis of NSAID conjugates 
(see below). Specifically, in rodents, bacteria are more abun-
dant throughout the small intestine, whereas in humans they are 
confined to the very distal parts of the small bowel. In addition, 
changes in the diet can alter the composition of the gut microbiota 
both in humans and mice (Satoh and Takeuchi, 2012; Tremaroli 
and Bäckhed, 2012). Therefore, one can assume that laboratory 
rodents, having a well-defined homogeneous diet compared with 
humans, will exhibit less interindividual variability in the micro-
biota profile caused by this factor than patients.
There are other differences between the human and the 
rodent GI tract; for example, in rodents, the ileum is much 
shorter (~2% of the total length of the small intestine) than the 
jejunum, whereas in humans, the ileum is more than half of the 
length of the small intestine (DeSesso and Jacobson, 2001). In 
spite of these structural and functional differences, the patho-
genesis of ulcer formation features many similarities across 
these species. For example, the distribution of ulcers along 
the small intestine shows the same pattern in humans, rats, 
and mice; the lesions appear focally and are more abundant in 
the distal parts of the intestine (Fujimori et al., 2010). In fact, 
both in rats (Atchison et al., 2000; Seitz and Boelsterli, 1998) 
and mice (Ramirez-Alcantara et al., 2009), most of the ulcers 
develop in quartile 3 and to a lesser extent in quartile 4, whereas 
the more proximal quartiles 1 and 2 are mostly free of lesions.
In most experimental studies, the NSAIDs were adminis-
tered po (to mimic the clinical situation). However, ip injec-
tion of diclofenac caused quantitatively and qualitatively very 
similar results as po administration (Seitz and Boelsterli, 
1998). This can be explained by pharmacokinetic behavior; 
the weakly acidic NSAIDs are protonated and hence primarily 
absorbed in the stomach. Thus, both after ip and po adminis-
tration, diclofenac will be delivered to the liver via the portal 
system, where the drug is conjugated to glucuronic acid (and 
also to sulfate or taurine), and large amounts excreted into bile. 
Consequently, the small intestine is exposed to the drug (plus 
metabolites) from the luminal side (see below). Interestingly, 
even topical administration of NSAIDs can lead to GI injury, 
as shown recently for diclofenac in hairless (but immunocom-
petent) mice (~600 µg, thrice per week). In these mice, peptic 
ulcers, esophageal ulcers, and GI bleeding occurred and greatly 
increased mortality (Lerche et al., 2011).
The most frequently used NSAIDs for modeling enteropathy 
include diclofenac (Atchison et al., 2000; LoGuidice et al., 2010, 
2012; Ramirez-Alcantara et al., 2009; Reuter et al., 1997; Seitz 
and Boelsterli, 1998), indomethacin (Anthony et al., 1993; Dial 
et al., 2008; Duggan et al., 1975; Fukumoto et al., 2011; Harusato 
et al., 2011; Watanabe et al., 2008; Wright et al., 1997; Takeuchi 
et al., 2010c; Yamada et al., 2011), and naproxen (Wallace et al., 
2011). All three compounds are weakly acidic (pK
a
, 4.0–4.5) 
nonselective COX-1/2 inhibitors, featuring a carboxylic acid 
moiety that is crucial for hepatic glucuronidation, hepatobiliary 
excretion, and enterohepatic cycling (see below). Therefore, 
most of the mechanistic insights into NSAID-induced intestinal 
injury stems from studies involving diclofenac, indomethacin, 
naproxen, or their congeners.
MECHANISMS OF MUCOSAL INJURY TO JEJUNUM 
AND ILEUM
Multi-Hit Concept
The molecular and cellular mechanisms underlying NSAID-
induced toxicity to the small intestinal mucosa are clearly distinct 
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from those in the stomach (Whittle, 2004); a detailed discussion 
of these differences can be found in a recent review (Wallace, 
2012). The major mechanisms underlying enteropathy are sum-
marized in Figure 1. On the one hand, and similar to the situa-
tion in the gastric mucosa, inhibition of COX-1 and/or COX-2 
(the therapeutic target) may contribute to GI toxicity (Hotz-
Behofsits et al., 2010; Sigthorsson et al., 2002; Tanaka et al., 
2002b). On the other hand, there are also significant off-target 
effects involved. Collectively, these adverse effects are largely 
a consequence of locally high concentrations of NSAIDs pre-
sent in the intestinal lumen and have been described as “topical 
effects” (Somasundaram et al., 1997). The exact concentrations 
of NSAIDs and/or their metabolites in the lumen are not known; 
however, biliary concentrations of parent drug plus glucuronide 
conjugates, following administration of a single ulcerogenic 
dose of diclofenac to rats, were found to be in the low millimolar 
range (Seitz and Boelsterli, 1998) and therefore clearly higher 
than the corresponding peak plasma concentrations, which are in 
the low micromolar range (LoGuidice et al., 2012). These topi-
cal (luminal) effects, which are still largely hypothetical, include 
uptake of the drug (and/or metabolites) into the enterocytes, pos-
sible bioactivation to reactive metabolites, and induction of endo-
plasmic reticulum (ER) stress (Tanaka et  al., 2005; Tsutsumi 
et al., 2004) and mitochondrial stress (LoGuidice et al., 2010; 
Ramirez-Alcantara et  al., 2009; Somasundaram et  al., 2000; 
Watanabe et al., 2011) and can be considered as a “first hit.”
After this initial insult to enterocytes, the mucosal epithe-
lia become more permeable, and bacterial lipopolysaccharide 
(LPS), present in the lumen, can penetrate deeper into the 
mucosa and activate toll-like receptor 4 (TLR4) on macrophages 
abundant in the lamina propria. This can lead to tumor necro-
sis factor–mediated cell injury and secondary activation of the 
innate immune system and recruitment of inflammatory cells 
to the site of injury (Watanabe et al., 2008). This inflammatory 
response can be considered a “second hit.”
A number of experimental approaches (mostly using chemi-
cal inhibitors or targeted gene deletion techniques) have pro-
vided evidence for the involvement of multiple mechanisms 
(involved in both first and second hit). This conclusion was 
primarily based on experimental findings in a variety of knock-
out mouse models that proved to be protected against NSAID 
enteropathy (see below).
Adverse Effects Mediated via COX Inhibition
The pharmacological target of NSAIDs is COX (prosta-
glandin endoperoxide synthase), which results in decreased 
levels of prostaglandins (Vane, 1971). Indeed, several studies 
in rodents have shown that, in the small intestine, the concen-
trations of PGE
2
 (which is the predominant prostaglandin in 
the intestinal mucosa) are substantially decreased after NSAID 
administration; for example, PGE
2
 concentrations were maxi-
mally decreased at 3 h after a single dose of indomethacin in 
mice, clearly preceding the development of ulcers (Takeuchi 
et  al., 2010a). Because prostaglandins have been implicated 
in a number of critical functions in the intestine, including 
Fig. 1. Putative mechanisms in the multiple-hit pathogenesis of NSAID-induced enteropathy. Dotted arrows, not supported by experimental evidence. Cx-1, 
mitochondrial complex I; ∆Ψ
m
, mitochondrial transmembrane potential; Mito perm, mitochondrial permeabilization; SI, small intestine.
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maintenance of blood flow, turnover of epithelial cells, and 
resolution of inflammation, the question may be raised whether 
the inhibition of prostaglandin synthesis by NSAIDs may be 
causally related to the enteric toxicity via loss of critical func-
tion. For example, endogenous PGE
2
 promotes the healing of 
small intestinal lesions by stimulating angiogenesis, mediated 
by the activation of the prostaglandin subtype receptor EP4. 
Thus, small doses of indomethacin, given after a large ulcero-
genic dose of indomethacin, significantly impaired ulcer heal-
ing for days; this was reversed by coadministration of an EP4 
agonist (Takeuchi et al., 2010c).
As to a causative role of prostaglandin synthesis inhibition 
in NSAID enteropathy, the two COX isoforms (COX-1 and 
COX-2, encoded by Ptgs1 and Ptgs2, respectively) could play 
different roles because these isoforms have distinct functions. 
Specifically, COX-1 is a constitutive form and is related to the 
development of inflammation, whereas COX-2 is an inducible 
form, involved in the resolution of inflammation. However, the 
respective role of the COX isoforms in the pathogenesis of small 
intestinal ulceration has remained controversial. Originally, it 
was hoped that the use of specific COX-1- or COX-2 knockout 
mice could help clarify this problem; however, homozygous 
Ptgs1−/− knockout mice, although having greatly decreased 
intestinal PGE
2
 levels, did not develop enteropathy. On the 
other hand, homozygous Ptgs2−/− mice did develop enteropathy 
(although different from the type induced by NSAIDs) yet 
had normal intestinal PGE
2
 levels (Langenbach et  al., 1999; 
Sigthorsson et al., 2002), suggesting that prostaglandins may 
not play a critical role in NSAID enteropathy. In line with this 
were the findings that, in rats, neither selective COX-1 inhibitors 
(e.g., SC-560) nor selective COX-2 inhibitors (e.g., rofecoxib, 
celecoxib) were able to induce intestinal damage. Meanwhile, 
it has become clear that small intestinal ulceration does only 
develop if an NSAID inhibits both COX-1 and COX-2 (as is the 
case for, e.g., diclofenac or indomethacin) (Tanaka et al., 2002a, 
b). Unfortunately, Ptgs1/2 double knockout mice are not viable 
and die shortly after birth; therefore, a combination of genetic 
deletion and pharmacological knockdown had to be utilized 
to provide the proof of concept. For example, both wild-type 
and homozygous Ptgs1−/− knockout mice reacted similarly to 
an ulcerogenic dose of indomethacin. However, the selective 
COX-2 inhibitor, celecoxib (which did not cause enteropathy 
in wild-type animals), caused ulceration in the small intestine 
of Ptgs1−/− mice (Sigthorsson et  al., 2002). The underlying 
mechanisms for a role of dual inhibition of COX-1 and COX-2 
are not entirely clear; however, the data are compatible with 
the concept that inhibition of COX-1 will upregulate COX-2 
and that PGE
2
 (derived from COX-2) prevents the adverse 
effects caused by COX-1 inhibition, helping maintain mucosal 
integrity (Takeuchi et al., 2010b); therefore, if both isoforms 
are inhibited together, enteropathy will develop.
The concept that inhibition of both COX isoforms leads to 
enteropathy was corroborated by a recent clinical report on a 
functional deficiency (several SNPs) of the gene coding for the 
cytosolic phospholipase A
2
-α (Adler et al., 2009). This enzyme 
normally releases arachidonic acid from membrane phospho-
lipids, which then is the substrate for COX (and for LOX), 
which converts arachidonic acid into prostaglandins (or leukot-
rienes, respectively). The patient carrying this mutation (and 
who was not taking any NSAIDs) repeatedly developed several 
sites of ulceration in the jejunum and ileum. These clinical find-
ings of this rare mutation leading to a rare phenotype support 
the conclusion that loss of protective function of prostaglan-
dins can lead to small intestinal ulceration. Experimental data 
support this conclusion; cPla
2
α knockout mice exhibited small 
intestinal ulcers although they were not severe (Sapirstein and 
Bonventre, 2000).
Alternatively, inhibition of the COX pathway by NSAIDs 
may shunt the metabolism of arachidonic acid into the other 
direction, i.e., activating the lipoxygenase (5-LOX) pathway. 
This could lead to oxidative stress due to increased production of 
superoxide from the 5-LOX-catalyzed peroxyradical formation 
and/or decrease in glutathione (GSH) due to reduction of the 
peroxyradicals. This mechanism has been disputed because 
certain NSAIDs that cause enteropathy do not only inhibit COX 
but also regulate 5-LOX. For example, diclofenac decreased 
leukotriene and 5-HETE formation in polymorphonuclear 
leukocytes (PMNs; Ku et al., 1986); however, this effect observed 
in vitro occurred at high concentrations only and did not seem 
to be related to a direct inhibition of 5-LOX but rather due to 
a disturbance of lipid metabolism. More recent evidence has 
provided clear evidence that diclofenac does not inhibit 5-LOX in 
rats (Maier et al., 2008). Therefore, increased oxidant stress from 
activation of the 5-LOX pathway is still a possible mechanism 
that could contribute to NSAID enteropathy. Although there 
is some evidence that leukotrienes could contribute to gastric 
mucosal injury (Burnett and Levy, 2012), the role of the 5-LOX 
pathway in NSAID enteropathy is still unclear.
FIRST HIT: TOPICAL EFFECTS
A topical effect is defined as a COX-independent impact 
caused by direct contact of intestinal epithelia with a drug pre-
sent in the lumen. Topical effects can be produced by a num-
ber of distinct mechanisms and include generation of reactive 
metabolites by enterocyte cytochrome P450s (CYP), ER stress, 
oxidative stress, or mitochondrial injury. Topical effects not only 
play a key role after po administration of an NSAID but are also 
equally important after ip or other parenteral routes due to hepa-
tobiliary excretion of metabolites and enterohepatic cycling.
Interactions With Biomembranes
One of the mechanisms by which NSAIDs can produce a top-
ical effect is a direct interaction with cellular membranes, alter-
ing their biophysical properties. For example, due to electrostatic 
and hydrophobic interactions between the anionic NSAIDs 
and the positively charged nitrogen in phosphatidylcholine, 
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the biophysical properties of the membrane can be altered, 
leading to changes in membrane fluidity, membrane instabil-
ity, and increased permeability to protons and bacterial tox-
ins (Lichtenberger et al., 2012). Although this is an attractive 
mecha nism in cultured cells, it is not clear to what extent this 
mechanism contributes to NSAID enteropathy in vivo.
Mitochondrial Injury
Most (but not all) NSAIDs that have been associated with 
enteropathy are uncouplers of oxidative phosphorylation 
(OXPHOS) in mitochondria, dissociating respiration from 
energy production. This feature, which is related to their molec-
ular structure and typical for lipophilic weak acids, suggests 
that mitochondrial energy depletion could be a mechanism 
contributing to enteropathy; indeed, it has been suggested 
that mitochondrial dysfunction could be the basis for the topi-
cal effect component of NSAID enteropathy (Mahmud et al., 
1996; Somasundaram et al., 1997). However, most functional 
studies on the effects of NSAIDs on oxygen consumption 
were performed in isolated mitochondria, and the in vivo rel-
evance is difficult to assess. In addition, NSAIDs have also 
been shown to inhibit certain complexes of the electron trans-
port chain.
Inhibition of Complex  I. A recent study demonstrated 
that certain NSAIDs, including diclofenac and indomethacin, 
inhibit rotenone-sensitive complex I  activity (measured by 
NADH consumption) in isolated mitochondria from rat 
duodenal mucosa or Caco-2 cells (Sandoval-Acuña et  al., 
2012). For example, the IC
50
 for diclofenac was 13µM, i.e., 
clearly in a noncytotoxic concentration range. This inhibition 
was reversible in the presence of quercetin, a ubiquinone 
(coenzyme Q, coQ) mimetic, suggesting that NSAIDs may 
block the ubiquinone binding site. These data are in contrast to 
earlier studies (Nadanaciva et al., 2007) where diclofenac did 
not inhibit complex I (but inhibited complex V) as determined 
by immunocapture mAb techniques; the discrepancy could be 
explained by the different experimental systems used.
Inhibition of complex I activity invariably leads to increased 
superoxide production in mitochondria, which could contribute 
to redox-sensitive signaling and cell death. Thus, these novel 
data provide an attractive hypothesis to explain both oxidant 
stress and toxicity of NSAIDs. However, the in vivo relevance 
of complex I inhibition is still unclear. Similarly, the relevance 
of recent findings in Saccharomyces cerevisiae yeast cells 
where diclofenac specifically inhibited complex III through 
interaction with subunit Rip1p (van Leeuwen et al., 2011) for 
the mammalian GI tract remains unknown.
Uncoupling of OXPHOS. Another inherent characteristic of 
many NSAIDs is their ability to act as uncouplers of OXPHOS. 
Interestingly, drug-induced mitochondrial uncoupling alone 
is not sufficient to induce overt small intestinal injury, but in 
combination with COX inhibition, enteropathy can develop. For 
example, an elegant series of experiments has revealed that the 
profen analog, R-2-phenylpropionic acid, which is not a COX 
inhibitor but which is an uncoupler of OXPHOS, does not cause 
enteropathy in mice when given alone (Hotz-Behofsits et al., 
2010). However, in combination with genetic or pharmacologic 
inhibition of COX-2 (e.g., by celecoxib administration), R-2-
phenylpropionic acid was able to induce small intestinal ulcers 
independently of mucosal prostaglandin levels. Similarly, the 
uncoupler 2,4-dinitrophenol, when instilled into the small bowel 
in rats, alone did not cause any apparent damage to the small 
intestine nor decrease intestinal prostaglandin levels. However, 
in combination with aspirin, which is not excreted via bile and 
which does not cause enteropathy when administered alone, 
the uncoupler caused ulcers in the small intestine to a similar 
extent as those induced by indomethacin (Somasundaram et al., 
2000). These experimental findings indicate that a combination 
of COX inhibition and topical effects, both of which uncouple 
mitochondrial OXPHOS, has a high potential of triggering 
small intestinal ulceration.
The mechanisms are incompletely understood, but uncou-
pling, which causes a dissipation of the mitochondrial inner 
transmembrane potential, ∆Ψ
m
, could have two consequences 
for enterocytes. First, the futile cycling of protons across the 
inner mitochondrial membrane leads to an attenuation of mito-
chondrial ATP production and a gradual depletion of cellular 
ATP. Second, a collapse of ∆Ψ
m
 could trigger the opening of 
the mitochondrial permeability transition (mPT) pore, poten-
tially leading to cell death if it happens in a sufficiently large 
number of mitochondria.
Mitochondrial Permeability Transition. Again, most 
experimental evidence that NSAIDs can induce mitochondrial 
permeabilization, followed by release of apoptogenic factors 
from the mitochondrial intermembrane space into the cytosol, 
stems from studies with isolated mitochondria; hence, the in 
vivo relevance is difficult to estimate. Increased mitochondrial 
(outer) membrane permeability can be triggered by different 
stimuli and executed by different mechanisms. One mechanism 
is the opening of the mPT pore, involving both the inner 
and outer membrane, which can be triggered by increased 
[Ca2+], oxidant stress, and/or a collapse of the mitochondrial 
membrane potential (∆Ψ
m
) (for recent reviews, see Baines 
[2009]; Halestrap [2009]). A number of NSAIDs indeed cause 
increases in cellular [Ca2+] and oxidant stress (Tanaka et  al., 
2005), and many of them are uncouplers of OXPHOS, resulting 
in a dissipation of ∆Ψ
m
 (Al-Nasser, 2000; Masubuchi et  al., 
2000, 2002; Tay et al., 2005; Uyemura et al., 1997). However, 
direct evidence that NSAIDs can cause mPT pore opening 
in the small intestinal mucosa has been limited to in vitro 
studies with cultured enterocytes, where high concentrations of 
diclofenac were able to cause cyclosporin A–sensitive changes 
in calcein/Co2+ fluorescence, an accepted indicator of the mPT 
(LoGuidice et al., 2010).
To ascertain whether the induction of mPT is causally 
involved in NSAID-induced ulceration, one would have to 
inhibit the mPT pore and monitor whether this would protect 
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from the subsequent development of enteropathy. This hypoth-
esis has been tested in vivo by targeting cyclophilin D (CypD), 
a mitochondrial matrix protein and key regulator of the mPT. 
Indeed, pretreatment of mice with alisporivir (Debio 025), a 
nonimmunosuppressive cyclosporin A analog that avidly binds 
to CypD and prevents it from interacting with mPT regula-
tory proteins, fully protected from enteropathy induced by 
diclofenac (LoGuidice et al., 2010). Similarly, diclofenac was 
not associated with small intestinal ulceration if administered 
to CypD-deficient (Ppif knockout) mice (LoGuidice et  al., 
2010), suggesting that the mitochondrial mPT plays a critical 
role in the development of NSAID ulceration.
Increased Intestinal Permeability. Another consequence 
of NSAID-induced decreases in mitochondrial ATP production 
is a loss of the gut barrier function. This can be quantitatively 
assessed by, e.g., orally administering dextran, a poorly 
absorbable high–molecular weight glycan, to mice. If the dextran 
molecule is labeled with the fluorescent marker FITC, then the 
increased intestinal permeability can be easily measured by 
determining the increases in FITC-specific fluorescence in the 
blood after NSAID administration (LoGuidice et  al., 2012). 
It has been suggested that decreased enterocytic ATP levels, 
rather than the loss of prostaglandins, may be responsible for 
the increased mucosal permeability (Montrose et  al., 2010). 
In accordance, in vivo exposure of the intestinal mucosa to an 
uncoupler (2,4-dinitrophenol) resulted in increased tight junction 
permeability (Nazli et al., 2004; Somasundaram et al., 2000).
Reactive Metabolites
Among the possible topical effects, toxicity due to reactive 
metabolites could also contribute to NSAID enteropathy. For 
example, reactive, electrophilic NSAID metabolites could be 
generated either in the liver and reach the small intestine via 
hepatobiliary transport or directly in the intestinal epithelia.
CYP-Mediated Oxidative Metabolites. Although the small 
intestine expresses a number of CYP forms (Kaminsky and 
Zhang, 2003; Komura and Iwaki, 2011), the role of oxidative 
metabolites generated in situ has not been clearly elucidated. 
In humans, it is primarily CYP2C8/9/19 that is involved in the 
oxidative biotransformation of many NSAIDs. Interestingly, 
rats lack Cyp2C in the intestine (although they express it 
abundantly in the liver) (Bruyère et al., 2009); therefore, it is 
tempting to speculate that the intestinal epithelial cells do not 
produce reactive NSAID intermediates via Cyp2C or that the 
topical effects are either mediated by the parent compound or 
by liver-derived metabolites.
In mice, however, there is evidence that intestinal CYPs may 
contribute to the “topical effect.” In an elegant recent study uti-
lizing an intestinal epithelium-specific CYP reductase knock-
out mouse (IE-Cpr-null mouse) to genetically eliminate all 
CYP-mediated oxidative metabolism (Zhu and Zhang, 2012), 
an ulcerogenic dose of diclofenac produced fewer ulcers than in 
wild-type animals. Because these mice were unable to generate 
the 5-hydroxy- or 4´-hydroxy metabolites from diclofenac (as 
well as the subsequent formation of reactive iminoquinones), 
the enterocytes exhibited much less electrophile stress (protein-
reactive intermediates and formation of reactive oxygen species 
[ROS]) than the wild-type mice. Accordingly, there were less 
diclofenac glutathione S-adducts found in enterocytes of these 
mice, and staining with an anti-diclofenac antibody revealed 
that there were less adducts present. Furthermore, pretreat-
ment with grapefruit juice, which inactivates certain CYPs in 
the small intestine, similarly protected mice from diclofenac 
enteropathy. Taken together, these novel data suggest that CYP-
mediated reactive intermediates, generated in enterocytes, may 
be involved in diclofenac enteropathy in mice.
However, the relevance of CYP-mediated NSAID bioacti-
vation in the GI in humans is still unclear. A study in nonhu-
man primates revealed that the expression levels of intestinal 
CYPs varied along the different segments of the small intestine. 
Specifically, in the cynomolgus monkey, transcript levels of a 
number of CYPs including CYP2C75 and 3A4 were higher 
in the proximal jejunum than in the distal ileum (Nakanishi 
et  al., 2010). Similarly, diclofenac-4´-hydroxylase acitivity 
was higher in the proximal parts of the jejunum (where ulcer 
formation is minimal) than in the more distal areas (where the 
majority of ulcers develop) (Nakanishi et al., 2011). If CYP-
mediated bioactivation of NSAIDs in the intestine is indeed 
causally related to the formation of ulcers, then this segmental 
distribution pattern does not reflect the incidence of ulceration.
Acyl Glucuronides and Iso-Glucuronides. It has been a 
matter of debate for many years whether acyl glucuronides 
(formed in the liver from carboxylic acid–containing NSAIDs) 
or iso-glucuronides (secondary metabolites formed after acyl 
migration of the aglycone along the sugar ring) (Dickinson, 
2011) may be causally involved in the topical effects associated 
with NSAID enteropathy (Boelsterli and Ramirez-Alcantara, 
2011). Although acyl glucuronides are electrophilic protein-
reactive intermediates and although covalent adducts have 
been detected on the enterocyte plasma membrane after in vivo 
administration of diclofenac (Atchison et  al., 2000), the fact 
that the adduct distribution along the small intestine is identical 
with the severity of ulceration could be merely correlative, 
rather than causal. In fact, recent data in which the enzyme-
catalyzed hydrolysis of diclofenac acyl glucuronide by intestinal 
bacteria was inhibited with a bacteria-specific β-glucuronidase 
inhibitor, and which resulted in protection from ulceration, 
suggest that the aglycone, rather than the glucuronide, may 
be involved in the topical effects associated with enteropathy 
(LoGuidice et al., 2012).
Oxidant Stress
There is insufficient and only indirect evidence that oxida-
tive stress is involved in NSAID enteropathy. For example, 
indomethacin significantly increased the expression of heme 
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oxygenase (HO-1) in mouse small intestinal mucosal tissue 
(Harusato et al., 2011). (HO-1 is an antioxidant enzyme that is 
induced by oxidant stress.) A recent study revealed that genetic 
deletion of Bach1, a transcriptional repressor of HO-1, not only 
led to highly increased upregulation of HO-1 but also fully pro-
tected mice from an ulcerogenic dose of indomethacin (10 mg/
kg, sc) (Harusato et  al., 2011); the underlying mechanisms, 
however, have remained unclear. Another indirect pathway that 
is activated by oxidant stress is the MAPK pathway (via JNK 
phosphorylation). Administration of the specific JNK inhibitor, 
SP600125, protected from diclofenac-induced enteropathy in 
an established mouse model of enteropathy (Ramirez-Alcantara 
et al., 2009). These effects could be induced by mitochondrial 
dysfunction, resulting in increased oxidant stress (see above); 
alternatively, oxidative stress could be a secondary effect trig-
gered by the inflammatory response and oxidative burst of cells 
of the innate immune system.
ER Stress Response
Studies based on molecular biomarkers revealed that 
NSAIDs induce an ER stress response in a number of cellu-
lar and in vivo models. For example, a recent toxicoproteom-
ics study in mice has confirmed that NSAIDs can cause ER 
stress in the GI (Ohyama et al., 2012). Mice were administered 
a high dose of diclofenac (100 mg/kg, ip), and pieces of the 
pyloric stomach were analyzed 6 h postdose. FD-LC-MS/MS 
analysis revealed that the ER stress marker protein GRP78 was 
highly increased in the diclofenac group; other increased pro-
tein levels were found for gastrin and HSP27 (both involved 
in apoptosis). Another biomarker of ER stress is CHOP (C/
EBP homologous protein, Gadd153), a transcription factor that 
becomes phosphorylated following ER stress and that induces 
mitochondria-mediated cell death (via inhibition of anti-apop-
totic Bcl-2 family proteins). For example, in cultured guinea 
pig gastric mucosal cells, NSAIDs induced apoptosis via Chop 
induction, whereas deletion of Chop by transfection of cells 
with a dominant-negative form of Chop, or isolation of perito-
neal macrophages from Chop-null mice, completely blocked 
NSAID-induced cell death (Tsutsumi et  al., 2004). In vivo, 
Chop induction not only preceded ulcer formation in mice that 
were given diclofenac, but homozygous Chop-knockout mice 
were refractory to diclofenac enteropathy (LoGuidice et  al., 
2010). Taken together, these data suggest a critical role of ER 
stress in the early topical effects of NSAID enteropathy.
SECOND HIT: INNATE IMMUNE SYSTEM AND 
INFLAMMATORY RESPONSE
The second stage of NSAID-induced injury to the small 
intestine is an inflammatory response. This is triggered by bac-
teria and bacteria-derived proinflammatory mediators invading 
mucosal layers beyond the epithelium. As a consequence, TLR-
mediated signaling pathways are activated, and neutrophils 
begin to infiltrate into the damaged areas. For example, neutro-
phils accumulate as early as 6 h after a challenge with indometh-
acin (Stadnyk et al., 2002). Also, proinflammatory mediators 
are activated in the small intestinal mucosa (Watanabe et al., 
2008). These events are a clear inflammatory response involv-
ing cells of the innate immune system. In contrast, the adaptive 
immune system does not seem to play a critical role in NSAID 
enteropathy as mice deficient in mature T and B cells (Rag2−/− 
mice) exhibited indomethacin-induced small intestinal injury 
comparable with wild-type control mice (Beck et al., 2000).
LPS/TLR4
TLRs recognize specific molecular patterns on pathogens 
including bacteria, and they trigger an inflammatory response. 
One of them, TLR4, is a receptor for LPS (endotoxin), a major 
component of gram-negative bacteria (Poltorak et  al., 1998), 
whereas other types of bacteria in the gut produce agonists for 
other TLRs. TLR4, which is expressed on monocytes and mac-
rophages in the lamina propria, has an extracellular leucine-
rich repeat domain and an intracellular interleukin-1R (IL-1R) 
signaling domain (Medzhitov et al., 1997). Upon activation by 
LPS, TLR4 signals via the accessory protein, MyD88, and acti-
vates NF-κB (Medzhitov et al., 1998), followed by activation 
of the proinflammatory cytokines tumor necrosis factor (TNF) 
and IL-1β.
To explore the role of TLR4 in the pathogenesis of NSAID 
enteropathy, a number of approaches have been used (Watanabe 
et al., 2008). First, pretreatment of mice with antibiotics that 
inhibit gram-negative enterobacteria but leave gram-positive 
bacteria intact (e.g., aztreonam), decreased indomethacin 
(10 mg/kg, po)-induced enteropathy by 95%. Second, TLR4-
mutant mice (C.C3H-Tlr4LPS-d) (Vogel et al., 1994) treated with 
indomethacin or diclofenac (60 mg/kg, po) exhibited markedly 
decreased small intestinal injury (by 80% for diclofenac). 
Finally, TLR4-knockout mice or MyD88-knockout mice were 
protected from indomethacin-induced enteropathy (by 79 and 
68%, respectively). These findings indicate that the TLR4-
MyD88-dependent signaling pathway is involved in amplifying 
NSAID-induced enteropathy.
High Mobility Group Box 1
High mobility group box 1 (HMGB1) belongs to a family 
of proteins that are released from cells undergoing necrosis 
(but not from apoptotic cells) (Wang et  al., 1999). HMGB1 
is also actively secreted from macrophages during inflam-
mation, where the protein acts as an inflammatory cytokine. 
HMGB1 is an endogenous ligand for TLR4 and other TLRs. 
A recent study has provided evidence that this pathway could 
be involved in NSAID-induced enteropathy (Nadatani et  al., 
2012). Immunoneutralizing HMGB1 or preventing its release 
from immune cells by chemical inhibitors attenuated indo-
methacin-induced enteropathy in mice, whereas exogenous 
HMGB1 potentiated the ulcerogenic effects. This modulation 
occurred through TLR4 activation (see above). This is clearly a 
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contributing factor during the second hit, and it is currently not 
known to what extent this mechanism is critical for NSAID-
induced enteropathy.
TNF
There is compelling evidence that TNF-α is causally involved 
in the pathogenesis of NSAID enteropathy. Normally, prosta-
glandins, and in particular the intestinal PGE
2
, inhibit TNF bio-
synthesis, whereas decreased levels of prostaglandins caused by 
NSAID exposure induce TNF synthesis (Bertrand et al., 1998). 
TNF appears to have multiple roles in NSAID enteropathy, but 
the exact mechanisms are not clear. On the one hand, a num-
ber of studies using TNF (or TNF receptor) knockout mice have 
clearly demonstrated that TNF is involved in enterocyte apop-
tosis and the subsequent inflammatory response in the small 
intestine. For example, indomethacin administration to TNF-null 
mice resulted in significant attenuation of small intestinal injury 
(Fukumoto et  al., 2011); in particular, the acute inflammatory 
response (PMN infiltration and upregulation of chemokines) was 
significantly reduced. Similarly, administration of an anti-TNF 
antibody to rats treated with indomethacin greatly protected from 
injury (Cury et al., 2008). On the other hand, TNF has been indi-
rectly linked with providing cytoprotective functions in the intes-
tinal mucosa by inducing COX-2 expression, which is mediated 
by transactivation of EGFR (Hobbs et al., 2011).
Apart from TNF, other cytokines/chemokines are also 
involved in the pathogenesis of NSAID enteropathy. For 
example, genetic deletion of IL-17A, a cytokine produced by 
T cells in the lamina propria that regulates the production of 
proinflammatory cytokines and chemokines, greatly protected 
from indomethacin enteropathy in mice, suggesting a role for 
IL-17A (Yamada et al., 2011).
Neutrophils
Massive infiltration of neutrophils at the areas of ulcera-
tion is a characteristic feature of NSAID enteropathy. This is 
not only evident from histopathology but also from a time-
dependent increase in myeloperoxidase activity (a biomarker 
for neutrophils) following challenge with NSAIDs (Watanabe 
et al., 2008). The question arises whether these neutrophils are 
actually contributing to the injury by aggravating the damage 
via ROS or proteases production or whether they are rather 
involved in resolving the tissue damage. A number of reports 
indicate that they might play a key role in aggravating the 
ulcerative injury. For example, neutrophil depletion by anti-
neutrophil serum resulted in massive reduction of indometh-
acin-induced enteropathy (Watanabe et  al., 2008). Similarly, 
administration of indomethacin to fucosyltransferase VII-
knockout mice (featuring impaired neutrophil recruitment) 
significantly decreased intestinal injury (Beck et  al., 2000). 
One mechanism by which these neutrophils could damage 
the tissue is by triggering an oxidative burst; indeed, homozy-
gous gp91phox-knockout mice (lacking the catalytic subunit of a 
phagocyte plasma membrane NADPH oxidase) were less sus-
ceptible to NSAID-induced damage than wild-type mice (Beck 
et al., 2000). One contributing mechanism of leukocyte recruit-
ment is the NSAID-mediated inhibition of COX-2; normally, 
COX-2 plays a role in protecting from infiltrating leukocytes, 
but a deficiency in COX-2 may open the avenue for leukocytes 
infiltrating into the mucosa and causing inflammation (Wallace 
et al., 2000).
Role of Underlying Inflammatory Disease
Because many patients who are treated with NSAIDs have 
an underlying inflammatory condition (the indication for 
drug treatment in the first place), the question may be asked 
whether this altered physiological state itself may contribute 
to the susceptibility to NSAIDs (Boelsterli, 2003). Supporting 
evidence for this concept stems from a rat model of adjuvant-
induced arthritis, in which diclofenac- or indomethacin-
induced enteropathy was aggravated after indomethacin or 
diclofenac, compared with wild-type rats (Kato et al., 2007). 
Interestingly, TLR4 mRNA and protein levels were both 
increased in the arthritic rats under basal conditions, and 
the number of macrophages in the lamina propria also was 
significantly increased in the arthritic rats. However, without 
NSAIDs exposure, no intestinal ulcers developed, likely 
because of normal prostaglandin levels. Thus, it is possible, but 
not well explored, that the disease against which the NSAIDs 
are prescribed can modulate the risk of developing enteropathy.
PHARMACOKINETIC DETERMINANTS
An interesting feature of NSAID enteropathy is the highly 
selective target tissue toxicity. Most NSAIDs are weak acids 
(pK
a
 3–6) and, depending on their degree of lipophilicity, 
mostly absorbed in the stomach (McCormack and Brune, 1987; 
Rainsford and Bjarnason, 2012). Thus, the distal part of the 
small intestinal mucosa is not the primary tissue exposed to the 
drugs after po administration. After both po and ip administra-
tion, the carboxylic acid–containing NSAIDs reach the liver, 
where they are glucuronidated and excreted into the biliary tree. 
The conjugated NSAIDs (or conjugated oxidative metabolites) 
then reach the small intestine, where the glucuronide moiety is 
cleaved off by bacterial β-glucuronidase, exposing the entero-
cytes to the aglycones (free parent NSAID or oxidative metabo-
lites). Thus, the pharmacokinetics is a major determinant that 
sets the stage for the primary interaction of NSAIDs with the 
mucosa (first hit) (Boelsterli and Ramirez-Alcantara, 2011).
Hepatobiliary Excretion and Enterohepatic Cycling of 
NSAID Glucuronides
In rodent models, NSAIDs (both parent drug and oxida-
tive metabolites) are conjugated in the liver to glucuronic acid 
(King et al., 2001; Peris-Ribera et al., 1991) or taurine (Mohri 
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et  al., 1998) and exported into bile against a concentration 
gradient via ATP-dependent transporters (Fig.  2). For exam-
ple, diclofenac glucuronides are transported across the apical 
membrane of hepatocytes into the bile canaliculus primarily by 
Mrp2 (ABCC2) (Seitz and Boelsterli, 1998) or Bcrp1 (ABCG2) 
(Lagas et al., 2010), whereas the specific carrier(s) for the tau-
roconjugates are less well defined. However, the exact metabo-
lite profile in bile has not yet been determined. In mice, only 
~4% of an orally administered dose of diclofenac was excreted 
in bile as acyl glucuronide (Lagas et al., 2010). Currently, it is 
not known whether and to what extent other conjugates (acyl 
glucuronides or phenol glucuronides of the 4´-hydroxy and 
5-hydroxy diclofenac, or even diglucuronides) are excreted 
through bile. However, a recent study using high-resolution 
mass spectrometric analysis of the metabolite profile has 
revealed that there are a number of distinct diclofenac glucu-
ronide species present and that phenol (ether) glucuronides and 
taurine conjugates are the most abundant metabolites in mouse 
plasma (Sarda et al., 2012) (Fig. 3). In addition, a portion of the 
acyl glucuronides can be converted into iso-glucuronides, iso-
mers formed after transacylation and migration of the aglycone 
along the sugar ring (Dickinson, 2011).
Early studies had indicated that NSAIDs undergoing enter-
ohepatic circulation are more likely to cause enteropathy than 
those without enterohepatic circulation, due to repeated and 
prolonged exposure of the gut mucosa to the drugs (Reuter 
et  al., 1997; Wax et  al., 1970). The key to this observation 
is the fact that, in the small intestine, the glucuronides must 
be cleaved to be reabsorbed. For example, for diclofenac, 
the bulk of the drug reaching the small intestinal lumen is 
conjugated, whereas the proportion of free parent drug was 
negligible (Lagas et al., 2010). One mechanism for the release 
of the aglycone is spontaneous hydrolysis of the glucuron-
ide, which is pH-dependent. For example, acyl glucuronides 
are unstable under alkaline conditions, whereas ether (phe-
nolic) glucuronides are generally more stable (Brunelle and 
Verbeeck, 1993). In humans, the pH of the distal small intes-
tine has been reported to be ~7.5 (Evans et al., 1988), but for 
rodents, the intestinal pH is clearly lower; in fact, mouse jeju-
num and ileum have a pH of 4.8, and rat jejunum and ileum 
have a pH of 5.1 and 5.9, respectively (McConnell et  al., 
2008). Interestingly, in the fasted state, the pH was slightly 
higher, i.e., 5.0 and 5.2 in mouse jejunum and ileum, respec-
tively, than in the fed state. Thus, it appears that, at least in 
rodents, the contribution of spontaneous hydrolysis of the 
glucuronides is small; therefore, other mechanisms are more 
prevalent, the most relevant one being enzymatic cleavage of 
the glucuronides by bacterial β-glucuronidase.
Role of Enteric Bacteria and Bacterial β-Glucuronidase
Approximately 100 trillion bacterial cells stably reside in the 
mammalian intestine (Vaishnava et al., 2011). They are impor-
tant for normal health, but they could also potentially induce 
harmful immune responses. Although in the colon a mucus 
layer acts as a physical barrier separating the mucosa from the 
bacteria, in the small intestine, such a thick mucus layer would 
interfere with absorption of nutrients. Instead, an antimicrobial 
peptide, RegIIIg, that is secreted by enterocytes, keeps the bac-
teria at a distance of ~50 µm (Vaishnava et al., 2011).
Enteric bacteria, in particular gram-negative bacteria, play 
an important role as a causative factor in NSAID enteropathy. 
Early studies with germ-free rodents or rodents given antibiotics 
clearly revealed that the elimination of the intestinal microflora 
significantly protected from NSAID-associated ulceration (Kent 
et al., 1969; Robert and Asano, 1977; Uejima et al., 1996). More 
recently, the key role of the enteric microflora, and in particular 
the specific composition, has been further highlighted in the fol-
lowing study. Rats treated with naproxen together with a PPI 
(omeprazole or lansoprazole) developed more severe intestinal 
ulceration and bleeding than naproxen alone–treated rats. This 
was primarily due to shifts in the numbers and types of enteric 
bacteria, including an 80% reduction of jejunal Actinobacteria 
and Bifidobacteria (Wallace et al., 2011). When germ-free mice 
were colonized with jejunal bacteria from PPI-treated rats, the 
severity of enteropathy was enhanced compared with coloniza-
tion with bacteria from vehicle control rats.
The reasons why bacteria can contribute to NSAID 
enteropathy are twofold. First, bacteria can invade deeper 
layers of the mucosa when the tight junctions become more 
permeable after a toxic insult and subsequently activate 
TLRs (see above). Second, and importantly, bacteria can 
metabolically convert NSAID glucuronides into aglycones 
by the action of β-glucuronidase, an enzyme that bacteria 
Fig. 2. Hepatic glucuronoconjugation of diclofenac (DCF), biliary export 
of glucuronides, and site-selective jejunal hydrolysis of glucuronides by bac-
terial β-glucuronidase. The local release of the aglycones causes electrophile 
stress and ER/mitochondrial stress. AG, acyl glucuronide; G, ether glucuronide.
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employ to scavenge for sugars. β-Glucuronidase activity, 
however, is not found in all enteric bacterial strains. 
For example, in an analysis of human colonic bacteria, 
the gene gus, which encodes for β-glucuronidase, was 
found in only nine strains of a total of 40 strains screened 
(including Roseburia hominis and Roseburia intestinalis, 
and Faecalibacterium prausnitzii [Dabek et al., 2008]) and 
correlated well with screens for activity measurements. 
However, other data indicate that ~50% of the human 
intestinal symbiotic bacteria of known sequence encode for 
a β-glucuronidase (Wallace et al., 2010).
An analysis of the relative activity of β-glucuronidase in the 
proximal part of the small intestine in comparison with that 
in the distal part of the small intestine across different species 
revealed two major findings. Firstly, the distal part exhibited 
higher bacterial β-glucuronidase activity than the proximal part 
(Hawksworth et al., 1971). Secondly, rodents (especially mice) 
have much higher intestinal β-glucuronidase activity than 
humans (Hawksworth et al., 1971). These data could perhaps 
help explain the higher severity of ulceration in the distal parts 
of the small intestine and provide a plausible explanation for the 
observed greater susceptibility of rodents to NSAIDs compared 
with humans. However, the relative contribution of bacterial 
β-glucuronidase (in the lumen) as opposed to the mammalian 
host β-glucuronidase (in enterocyte ER and lysosomes) has not 
yet been clearly determined genetically.
NOVEL STRATEGIES AND PHARMACOLOGICAL 
APPROACHES TO PROTECT FROM NSAID 
ENTEROPATHY
Some current approaches to avoid GI damage following 
NSAID therapy include the use of selective COX-2 inhibi-
tors, the development of NO- or H
2
S-releasing NSAIDs, and 
the coadministration of PPIs (to reduce gastropathy only). 
However, currently, there are no approved pharmacological 
interventions that can treat or fully prevent NSAID-induced 
enteropathy (Park et  al., 2011; Wallace, 2012); compounds 
aimed at reducing the inflammatory response or to stimulate 
prostaglandin-mediated effects have been used, but with limited 
efficacy and/or adverse effects (Park et al., 2011; Wallace, 2012). 
Importantly, most experimental and therapeutic approaches 
to alleviate enteropathy have focused on the second hit, the 
inflammatory component, whereas approaches to protect from 
the first hit (mitochondrial stress, ER stress, electrophile stress) 
or even upstream mechanisms (delivery of glucuronides and 
local release of the aglycones) have not been fully explored.
Due to the multiple mechanisms involved in NSAID enter-
opathy, several strategies can be applied, including prostaglan-
din cotherapy and inhibition of mitochondrial signaling of cell 
death. However, a novel and promising approach is the targeted 
inhibition of aglycone release in the small intestine by specific 
bacterial enzyme inhibitors.
Fig. 3. Metabolic pathways of diclofenac (DCF) conversion to its oxidative (CYP-mediated) and tauro- or glucuronoconjugates. Thick arrows, prevalent 
pathways. AG, acyl glucuronide; G, ether glucuronide; iso-AG, transacetylated isomers of DCF acyl glucuronide.
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Prostaglandin Cotherapy and Other Mucosa-Protective Agents
Because of the postulated protective effects of some pros-
taglandins, cotherapy with PGs or PG analogs theoretically 
should result in an at least partial protection from NSAID-
induced enteropathy (Takeuchi et  al., 2010a). Clinical data 
demonstrating efficacy were lacking until the recent introduc-
tion of capsule endoscopy. A study using this novel diagnostic 
technique has demonstrated that coadministration in patients of 
misoprostol, a PGE
1
 analog, reduced small intestinal mucosal 
lesions associated with diclofenac therapy (3 × 25 mg/day for 
2 weeks) by 75% (Fujimori et  al., 2009). Although this is a 
promising avenue for further investigations, certain adverse 
effects, including diarrhea, abdominal pain, and the inconven-
ience of multiple daily dosing, may limit this approach. In addi-
tion, misoprostol could not be used in women of child-bearing 
potential due to its abortifacient activity.
An alternative clinical approach has been the use of rebami-
pide, a mucosa-protective agent used for treating gastric 
ulcers, in NSAID-induced enteropathy (Fujimori et al., 2011). 
Although rebamipide has certain ulcer-preventive effects, the 
mechanisms are not understood.
Pharmacological Inhibition of Mitochondrial Stress
Mitochondrial permeabilization and release of mitochondrial 
mediators signaling in cell death pathways are regulated by a 
number of factors; a key regulator of the mPT pore seems to be 
CypD (see above). Cotreatment of mice with an ulcerogenic 
dose of diclofenac and the selective mitochondrial CypD inhib-
itor, alisporivir (Debio 025), afforded significant protection 
against the NSAID-induced intestinal permeability increase 
and enteropathy (LoGuidice et  al., 2010). Because alispori-
vir is undergoing clinical trials as an agent to treat hepatitis 
C through preventing mitochondrial dysfunction, its enteric-
protective potential should also be investigated in patients 
(Quarato et al., 2012).
Pharmacological Inhibition of Bacterial β-Glucuronidase
Site-specific delivery of bile-derived NSAID glucuronides 
and local release of the aglycones in the jejunal/ileal lumen 
by bacterial enzymes are key mechanisms in the pathogene-
sis of enteropathy (see above). The recent demonstration that 
the selective inhibition of bacterial β-glucuronidases with 
a bacteria-specific chemical inhibitor alleviates diclofenac-
induced small intestinal ulceration in mice strongly supports 
this concept (LoGuidice et al., 2012). These novel small mol-
ecule bacterial β-glucuronidase inhibitors belong to a class of 
compounds that have proven effective in protecting against 
the toxicity of CPT-11 (irinotecan) through the same mecha-
nism (Ahmad et  al., 2011; Wallace et  al., 2010). The bacte-
rial β-glucuronidase inhibitor employed has no effects on the 
mammalian β-glucuronidase and is not lethal to either human 
or bacterial cells. Thus, it is considered selective and nontoxic 
in studies conducted to date. Because this pharmacokinetic 
interaction apparently did not alter the systemic exposure to 
the pharmacologically active parent diclofenac (the major-
ity of biliary glucuronides are ring-hydroxylated metabolites, 
rather than the parent drug) (LoGuidice et al., 2012), it is likely 
that the desired anti-inflammatory and analgesic effect of the 
NSAID would remain unaffected. Further pharmacokinetic and 
pharmaco-/toxicodynamic characterization of these small mol-
ecule inhibitors is currently under way.
CONCLUSIONS
The prescription of nonselective COX-1/2 inhibitors 
against rheumatoid disorders is likely to increase with aging 
populations and because many health professionals are reluctant 
to prescribe selective COX-2 inhibitors due to their potential 
for cardiovascular complications. Furthermore, NSAIDs find 
increasing clinical application as anticancer drugs or to treat 
Alzheimer’s disease. Therefore, it is likely that NSAID-induced 
enteropathy will be increasingly diagnosed. Recent advances 
in understanding the mechanisms of small bowel ulceration 
have clearly indicated that the pathogenesis is distinct from 
that in the upper GI tract. It has become equally clear that 
hepatobiliary delivery of NSAID glucuronides to the jejunum/
ileum, followed by site-selective release of the aglycones by 
bacterial β-glucuronidase, is a major determinant of enteropathy. 
This is followed by enteric bioactivation, electrophile stress, 
and mitochondrial injury to enterocytes (first hit), followed 
by an inflammatory response (second hit). Thus, bacterial 
β-glucuronidase has a high potential to becoming a potentially 
novel therapeutic target in treating NSAID-induced enteropathy.
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